Sign in Subscribe

JPMorgan Sees 127% Upside in Camp4 Therapeutics as It Upgrades to Overweight on CMP-002 Potential

JPMorgan upgrades Camp4 to Overweight, sees strong upside from CMP-002, with trials planned in 2026 and promising early results.

JPMorgan Sees 127% Upside in Camp4 Therapeutics as It Upgrades to Overweight on CMP-002 Potential
"CMP-002 is Camp4 Therapeutics’ lead drug candidate, an intrathecally delivered antisense oligonucleotide (ASO) that targets a specific regRNA (regulatory RNA) to treat SYNGAP1-related disorder." Credit: Camp4
Already have an account? Sign in.